Psychedelic Drug Stock's Biggest Investor Closes $125 Million Funding Round

Psychedelic Drug Stock's Biggest Investor Closes $125 Million Funding Round

Atai Life Sciences, a company that backs Compass Pathways (CMPS) and other psychedelic drug developers, said Monday that it had closed a $125 million funding round, the latest infusion for an industry that more investors believe has the potential for mental-health breakthroughs. The size of the funding eclipses the $80 million raised by Compass, announced in April, as well as...